l General Information |
Product Name | BAY-X-1005 |
General description | Inhibition of soluble epoxide hydrolase by AUDA inhibits the metabolism of epoxyeicosatrienoic acids (EETs) and protects end-organs against the damaging effects of salt-sensitive hypertension. AUDA also renders protection against myocardial ischemia-reperfusion injury and cerebral ischemia. |
Synonym | DG 031, Velifapon, Veliflapon; α-Cyclopentyl-4-(2-quinolinylmethoxy)-(R)-benzeneacetic acid, (αR)-α-Cyclopentyl-4-(2-quinolinylmethoxy)-benzeneacetic acid, |
Purity | ≥98.0%(HPLC) | CAS Number | 128253-31-6 |
Formula | C23H23NO3 | Molecular Weight | 361.43 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White to Beige Solid |
Solubility(25℃) | DMSO | ~5mg/mL |
l Biological Information |
Biochem/Physiol Actions | Bay-X-1005 is a potent inhibitor of 5-lipoxygenase activating protein (FLAP). Bay-X-1005 inhibits A23187-induced LTB4 production in human leucocytes with an IC50 value of 220 nM, and blocks IgE mediated airway contractions. |
l Storage |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
